Ionis Pharmaceuticals IONS
$26.58 −$0.64 (-2.35%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $26.76 +0.68%
Open$26.93
Prev close$27.22
Day range$26.53 – $28.07
Volume3.19M
Market cap$4.43B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$242.72M+54.9% YoY
Operating profit-$130.68M+18.4% YoY
Net profit-$109.97M+14.5% YoY
Diluted EPS-$0.66+17.5% YoY
Free cash flow-$193.63M-39.9% YoY
Operating cash flow-$179.42M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin98.2%
Operating margin-58.8%
Net margin-56.9%
Return on equity-108.1%
Return on assets-18.4%
Return on invested capital-24.5%
Current ratio5.43
Liabilities / assets86.5%
Cash & investments$1.88B
Total debt$1.63B
Net cash (debt)$254.72M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $242.72M | $267.95M | $246.09M | $943.71M | $203.33M |
| Total Operating Revenue | $242.72M | $267.95M | $246.09M | $943.71M | $203.33M |
| Cost of Revenue | $3.32M | $2.74M | $3.00M | $15.91M | $7.96M |
| Gross Profit | $239.40M | $265.21M | $243.09M | $927.80M | $195.37M |
| Operating Expense | $370.08M | $367.51M | $360.57M | $1.31B | $409.85M |
| Selling and Admin Expenses | $154.20M | $150.40M | $150.40M | $393.90M | $130.20M |
| -General & Admin Expense | $154.20M | $150.40M | $150.40M | $393.90M | $130.20M |
| Research & Development | $215.88M | $217.11M | $210.17M | $915.62M | $279.65M |
| Operating Profit | -$130.68M | -$102.30M | -$117.48M | -$381.72M | -$214.47M |
| Net Non-Operating Interest Income (Expense) | -$8.73M | -$22.11M | -$22.54M | -$90.58M | -$22.76M |
| Non-Operating Interest Expense | $7.03M | $20.51M | $20.34M | $84.28M | $21.06M |
| Total Other Finance Costs | $1.70M | $1.60M | $2.20M | $6.30M | $1.70M |
| Other Income (Expense) | $29.35M | $11.04M | $47.61M | $92.63M | $9.23M |
| Gain on Sale of Security | $29.07M | $10.05M | $48.07M | $107.99M | $25.52M |
| Other Non-Operating Income (Expenses) | $277,000.00 | $987,000.00 | -$456,000.00 | -$15.36M | -$16.29M |
| Pretax Profit | -$110.11M | -$113.38M | -$92.31M | -$379.60M | -$227.92M |
| Tax | -$141,000.00 | $1.26M | $218,000.00 | $1.79M | $1.48M |
| Net Profit | -$109.97M | -$114.65M | -$92.53M | -$381.39M | -$229.39M |
| Profit from Continuing Operations | -$109.97M | -$114.65M | -$92.53M | -$381.39M | -$229.39M |
| Net Income to Parent Company | -$109.97M | -$114.65M | -$92.53M | -$381.39M | -$229.39M |
| Net Income to Common Stockholders | -$109.97M | -$114.65M | -$92.53M | -$381.39M | -$229.39M |
| Basic EPS | -$0.66 | -$0.69 | -$0.56 | -$2.38 | -$1.41 |
| Diluted EPS | -$0.66 | -$0.69 | -$0.56 | -$2.38 | -$1.41 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $2.91B | $2.99B | $3.45B | $3.52B | $3.52B |
| Total Current Assets | $2.36B | $2.49B | $2.94B | $2.99B | $2.99B |
| Cash and Cash Equivalents & Short-Term Investments | $1.88B | $2.05B | $1.92B | $2.68B | $2.68B |
| -Cash and Cash Equivalents | $296.30M | $350.07M | $173.38M | $372.26M | $372.26M |
| -Short Term Investments | $1.59B | $1.70B | $1.75B | $2.31B | $2.31B |
| Receivables | $88.34M | $58.85M | $73.68M | $66.06M | $66.06M |
| -Other Receivables | $88.34M | $58.85M | $73.68M | $66.06M | $66.06M |
| Inventory | $28.58M | $50.83M | $5.56M | $10.05M | $10.05M |
| Other Current Assets | $360.68M | $327.01M | $306.08M | $237.09M | $237.09M |
| Total Non-Current Assets | $551.09M | $503.23M | $513.02M | $533.20M | $533.20M |
| Net PPE | $390.09M | $386.69M | $377.47M | $361.60M | $361.60M |
| -Gross PPE | $390.09M | $386.69M | $377.47M | $470.68M | $470.68M |
| Other Non-Current Assets | $161.00M | $116.54M | $135.56M | $171.60M | $171.60M |
| Total Liabilities | $2.52B | $2.55B | $2.96B | $3.03B | $3.03B |
| Total Current Liabilities | $435.29M | $315.64M | $716.59M | $781.57M | $781.57M |
| Payables | $27.22M | $50.58M | $28.90M | $30.80M | $30.80M |
| -Accounts Payable | $27.11M | $47.70M | $26.03M | $28.08M | $28.08M |
| -Total Tax Payable | $109,000.00 | $2.88M | $2.87M | $2.71M | $2.71M |
| Current Accrued Expenses | $116.18M | $115.78M | $126.55M | $106.09M | $106.09M |
| Short-Term Debt and Capital Lease Obligation | $22.12M | – | $432.50M | $454.69M | $454.69M |
| -Current Debt | $22.12M | – | $432.50M | $454.69M | $454.69M |
| Current Deferred Liabilities | $70.20M | $73.84M | $69.20M | $73.76M | $73.76M |
| Other Current Liabilities | $138.19M | $25.15M | $23.39M | – | – |
| Total Non-Current Liabilities | $2.08B | $2.24B | $2.24B | $2.25B | $2.25B |
| Long Term Debt and Capital Lease Obligation | $1.61B | $1.61B | $1.61B | $1.61B | $1.61B |
| -Long Term Debt | $1.34B | $1.35B | $1.35B | $1.35B | $1.35B |
| -Long Term Capital Lease Obligation | $262.48M | $262.48M | $259.22M | $262.38M | $262.38M |
| Non-Current Deferred Liabilities | $48.76M | $63.03M | $75.75M | $92.00M | $92.00M |
| Other Non-Current Liabilities | $427.84M | $562.57M | $557.77M | $551.35M | $551.35M |
| Total Equity | $393.64M | $439.74M | $491.41M | $489.09M | $489.09M |
| Stockholders' Equity | $393.64M | $439.74M | $491.41M | $489.09M | $489.09M |
| Capital Stock | $166,000.00 | $166,000.00 | $166,000.00 | $163,000.00 | $163,000.00 |
| -Common Stock | $166,000.00 | $166,000.00 | $166,000.00 | $163,000.00 | $163,000.00 |
| Additional Paid-In Capital | $3.38B | $3.31B | $3.25B | $3.15B | $3.15B |
| Retained Earnings | -$2.95B | -$2.84B | -$2.72B | -$2.63B | -$2.63B |
| Gains/Losses Not Affecting Retained Earnings | -$39.82M | -$33.90M | -$31.02M | -$25.28M | -$25.28M |
| Restricted Cash | – | – | $632.51M | – | – |
| -Accumulated Depreciation | – | – | – | -$109.08M | -$109.08M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$179.42M | $565.53M | -$792.82M | -$268.58M | -$137.71M |
| Net cash flow from continuing operations | -$179.42M | $565.53M | -$792.82M | -$268.58M | -$137.71M |
| Net Income from Continuing Operations | -$109.97M | -$114.65M | -$92.53M | -$381.39M | -$229.39M |
| Gain/Loss from Continuing Operations | -$8.71M | $10.62M | -$22.54M | $4.06M | $17.14M |
| Depreciation & Depletion & Amortization | $7.86M | $7.64M | $7.45M | $22.69M | $7.34M |
| Other Non-Cash Items | -$7.82M | $8.46M | $7.84M | $27.13M | $5.70M |
| Change in Working Capital | -$101.14M | $611.21M | -$730.12M | -$51.22M | $23.86M |
| -Change in Receivables | -$29.50M | $14.84M | -$7.63M | $26.13M | -$41.45M |
| -Change in Inventory | -$22.00M | -$24.96M | $338,000.00 | -$13.67M | $926,000.00 |
| -Change in Payables and Accrued Expense | -$9.66M | $27.93M | -$62.28M | $36.59M | -$9.45M |
| -Change in Other Current Assets | -$22.08M | -$30.88M | -$7.39M | -$33.21M | $90.28M |
| -Change In Other Working Capital | -$17.91M | $624.27M | -$653.17M | -$67.05M | -$16.45M |
| Net cash flow from investing | $99.88M | $23.50M | $536.82M | -$277.78M | -$419.51M |
| Net Cash Flow from Continuing Investing Activities | $99.88M | $23.50M | $536.82M | -$277.78M | -$419.51M |
| Net PPE Purchase and Sale | -$12.71M | -$16.08M | -$21.76M | -$51.44M | -$21.29M |
| Net Intangibles Purchase and Sale | -$1.50M | -$2.15M | -$1.49M | -$5.64M | -$1.37M |
| Net Investment Purchase and Sale | $114.09M | $41.73M | $560.07M | -$220.69M | -$396.85M |
| Financing Cash Flow | $25.79M | -$412.29M | $57.26M | $675.84M | $591.18M |
| Net Cash Flow from Continuing Financing Activities | $25.79M | -$412.29M | $57.26M | $675.84M | $591.18M |
| Net Issuance Payments Of Debt | -$43,000.00 | -$432.55M | -$44,000.00 | $502.19M | $502.31M |
| Net Common Stock Issuance | $25.83M | $20.26M | $57.30M | $192.60M | $107.82M |
| Ending Cash Balance | $296.30M | $350.07M | $173.38M | $372.26M | $372.26M |
| Net Change in Cash | -$53.75M | $176.73M | -$198.74M | $129.48M | $33.96M |
| Beginning Cash Balance | $350.07M | $173.38M | $372.26M | $242.08M | $338.34M |
| Effect of Exchange Rate Changes | -$11,000.00 | -$50,000.00 | -$138,000.00 | $702,000.00 | -$43,000.00 |
| Free Cash Flow | -$193.63M | $547.30M | -$816.07M | -$325.67M | -$160.37M |
| Net Other Financing Charges | – | – | – | -$18.95M | – |
No comments yet — be the first to weigh in on IONS.
Sign in to join the discussion.